Consequently, the plasma half-life of the GLP-1 albumin fusion was reduced from 1.3 days to 0.9 days in the human FcRn Tg32 mice
Multiple banks, such as BMO Capital Markets, 8 Morningstar 9 and Goldman Sachs 10 expect the market to grow to or beyond $100bn by 2030, with some, such as JP Morgan, 11 predicting as high as $140bn by 2032
The latter, while providing valuable real-world signals, are inherently susceptible to confounding by indication and selection bias, as patient characteristics and co-morbidities may differ significantly between treatment groups
Brand-Name GLP-1 Medications: Ozempic and Wegovy (semaglutide) Mounjaro and Zepbound (tirzepatide) FDA-approved with extensive clinical trial data Manufactured by pharmaceutical companies (Novo Nordisk, Eli Lilly) Cost $900-$1,350 per month without insurance May be covered by insurance (with restrictions) Come in pre-filled injection pens Compounded GLP-1 Medications: Same active ingredients as brand-name versions Made by FDA-registered compounding pharmacies Cost $199-$599 per month Not typically covered by insurance Available due to ongoing medication shortages May come in vials requiring manual injection or pre-filled syringes Are Compounded GLP-1s Safe
It sounded too good to be true, but I decided to give them a try, and Im so glad I did
Two authors assessed the risk of bias for each study through five aspects: random sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting
